#United States #San Francisco #Hagens Berman #REZDIFFRA #Madrigal Pharmaceuticals

Investigation Launched into Madrigal Pharmaceuticals

In a significant development in the pharmaceutical sector, Hagens Berman, a prominent national law firm specializing in complex securities litigation, has announced an investigation concerning Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). This inquiry primarily centers around serious whistleblower allegations that suggest the company may have misrepresented or concealed crucial information related to the integrity of clinical safety data and regulatory compliance regarding its medication, Rezdiffra (resmetirom).

Background of the Allegations

The investigation commenced after disclosures in Madrigal's Quarterly Report, specifically filed under Form 10-Q. On October 9, 2026, Dr. Michael Charlton, who previously held the position of Senior Vice President and Head of Clinical Development at Madrigal, lodged a whistleblower complaint with allegations of severe deficiencies within the clinical trials. Notably, these allegations indicate that senior leaders at Madrigal overlooked critical internal warnings about suppressed data related to adverse liver injuries, which could potentially undermine the drug's safety profile.

Furthermore, the complaint outlines discrepancies in efficacy data presented by the company. It asserts that the reported results could not be adequately reconciled with the original source data, raising serious concerns about the reliability of the information shared with investors and regulatory agencies. Another alarming claim made in the whistleblower complaint points to improper oversight by the Board of Directors, where an unblinded member reportedly had undue influence over the adjudication of clinical outcomes.

Market Reaction

Following the release of these allegations, Madrigal Pharmaceuticals witnessed a significant decline in its stock price, plummeting by $34.84 per share or over 8%, and closing at $396.32 amid heavy trading. This drop reflects investor concerns regarding the potential implications of the allegations on the company’s future and the safety of Rezdiffra, a drug recently under scrutiny.

Reed Kathrein, the Hagens Berman attorney leading the investigation commented, “Our focus is to track when Madrigal executives were first alerted to these clinical trial irregularities and investigate whether investors were misled regarding the safety profile and data reliability of Rezdiffra.”

Seeking Input from Investors

Investors who have experienced significant financial losses due to their dealings in Madrigal's securities are encouraged to reach out directly to the Hagens Berman legal team. The firm is particularly interested in gathering trading information that might contribute to their investigation. Those familiar with non-public information that could assist or clarify these claims are also urged to step forward. Whistleblowers may find a further incentive through the SEC Whistleblower program, which can reward them with up to 30% of any successful recovery made by the SEC if their information leads to a successful enforcement action.

The law firm's history showcases its commitment to corporate accountability. Hagens Berman is recognized for securing substantial settlements in various cases concerning corporate negligence and wrongful conduct, having achieved outcomes exceeding $2.9 billion for perpetrators of corporate misconduct. The firm represents not just investors but also whistleblowers and other parties affected by corporate malpractices.

Conclusion

As the investigation unfolds, it raises essential questions about clinical safety data integrity in the pharmaceutical industry. Participants in the market, especially investors in Madrigal Pharmaceuticals, would do well to remain informed about the progression of this inquiry and the potential implications it may carry for both the company and the drug it supports, Rezdiffra. Updates and further information regarding Hagens Berman’s investigation will likely emerge as the situation develops.